Cart
sales@molnova.com
Tetomilast
CAS No. 145739-56-6
Tetomilast ( OPC-6535 )
Catalog No. M11976 CAS No. 145739-56-6
Tetomilast (OPC-6535) is a superoxide anion production inhibitor that inhibits PDE4 and proinflammatory functions.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTetomilast
-
NoteResearch use only, not for human use.
-
Brief DescriptionTetomilast (OPC-6535) is a superoxide anion production inhibitor that inhibits PDE4 and proinflammatory functions.
-
DescriptionTetomilast (OPC-6535) is a superoxide anion production inhibitor that inhibits PDE4 and proinflammatory functions of leukocytes including superoxide production and cytokine release; attenuates sepsis-induced acute lung injury.COPD Phase 2 Clinical
-
SynonymsOPC-6535
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number145739-56-6
-
Formula Weight370.42
-
Molecular FormulaC19H18N2O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=NC(C2=CSC(C3=CC=C(OCC)C(OCC)=C3)=N2)=CC=C1)O
-
Chemical Name6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schreiber S, et al. Gastroenterology. 2007 Jan;132(1):76-86.
2. Bloomfield GL, et al. J Surg Res. 1997 Sep;72(1):70-7.
3. Ejiri S, et al. Transplant Proc. 2000 Mar;32(2):318-21.
2. Bloomfield GL, et al. J Surg Res. 1997 Sep;72(1):70-7.
3. Ejiri S, et al. Transplant Proc. 2000 Mar;32(2):318-21.
molnova catalog
related products
-
CRT0273750
CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.
-
BW-A78U
BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
